HER2-negative metastatic breast cancer patients receiving first-line docetaxel: Survival data and prognostic factors

被引：0
|
作者：
Deblock, M. [1 ]
Esterni, B. [1 ]
Tarpin, C. [1 ]
Charaffe-Jauffret, E. [1 ]
Extra, J. M. [1 ]
Viens, P. [1 ]
Goncalves, A. [1 ]
机构：
[1] Inst Paoli Calmettes, Marseille, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1105
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment
    Goncalves, A.
    Deblock, M.
    Esterni, B.
    Toiron, Y.
    Tarpin, C.
    Charaffe-Jauffret, E.
    Chabannon, C.
    Extra, J. M.
    Viens, P.
    Borg, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [3] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
    Llombart-Cussac, Antonio
    Pivot, Xavier
    Biganzoli, Laura
    Cortes-Funes, Hernan
    Pritchard, Kathleen I.
    Pierga, Jean-Yves
    Smith, Ian
    Thomssen, Christoph
    Srock, Stefanie
    Sampayo, Miguel
    Cortes, Javier
    BREAST, 2014, 23 (05): : 656 - 662
  • [5] Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study
    Koszo, Renata
    Santha, Dra
    Budi, Laszl
    Erfan, Jzsef
    Gyorfy, Karoly
    Horvath, Zsolt
    Kocsis, Judit
    Landherr, Laszlo
    Hitre, Erika
    Mahr, Karoly
    Pajkos, Gabor
    Papai, Zsuzsanna
    Kahan, Zsuzsanna
    PATHOLOGY & ONCOLOGY RESEARCH, 2017, 23 (03) : 505 - 511
  • [6] Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer
    Babacan, Taner
    Efe, Orhan
    Hasirci, Ahmet S.
    Demirci, Fatih
    Buyukhatipoglu, Hakan
    Balakan, Ozan
    Sarici, Furkan
    Kertmen, Neyran
    Esin, Ece
    Akin, Serkan
    Ates, Ozturk
    Aksoy, Sercan
    Sever, Ali R.
    Altundag, Kadri
    TUMORI JOURNAL, 2015, 101 (04): : 418 - 423
  • [7] Primary endpoints in first-line trials in patients with HER2-negative/-unknown metastatic breast cancer (MBC)
    Kuemmel, S.
    Mueller, V
    Lux, M. P.
    Weyer, G.
    Pintoffl, J. P.
    Jackisch, C.
    ONKOLOGIE, 2012, 35 : 66 - +
  • [8] Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
    Christoph Zielinski
    Istvan Lang
    Semir Beslija
    Zsuzsanna Kahan
    Moshe J Inbar
    Salomon M Stemmer
    Rodica Anghel
    Damir Vrbanec
    Diethelm Messinger
    Thomas Brodowicz
    British Journal of Cancer, 2016, 114 : 163 - 170
  • [9] Endocrine therapy or chemotherapy as first-line therapy in hormone receptorepositive HER2-negative metastatic breast cancer patients
    Jacquet, E.
    Lardy-Cleaud, A.
    Pistilli, B.
    Franck, S.
    Cottu, P.
    Delaloge, S.
    Debled, M.
    Vanlemmens, L.
    Leheurteur, M.
    Guizard, A. V.
    Laborde, L.
    Uwer, L.
    Jacot, W.
    Berchery, D.
    Desmoulins, I.
    Ferrero, J. M.
    Perrocheau, G.
    Courtinard, C.
    Brain, E.
    Chabaud, S.
    Robain, M.
    Bachelot, T.
    EUROPEAN JOURNAL OF CANCER, 2018, 95 : 93 - 101
  • [10] Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status
    Goncalves, Anthony
    Deblock, Mathilde
    Esterni, Benjamin
    Tarpin, Carole
    Bertucci, Francois
    Gilabert, Marine
    Charafe-Jauffret, Emmanuelle
    Jacquemier, Jocelyne
    Houvenaeghel, Gilles
    Extra, Jean-Marc
    Viens, Patrice
    ANTI-CANCER DRUGS, 2009, 20 (10) : 946 - 952
12345